The National Institutes of Health (NIH) sponsored Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a public-private partners involved with determining where federal research dollars are…
Recently, the results of a new ivermectin study out of Columbia were reported in the medical journal JAMA. Led by Eduardo Lopez Medina, MD, a physician…
A recent study sponsored by Massachusetts General Hospital in collaboration with the National Multiple Sclerosis Society and Pillsy Inc. was based on the assumption that…
AstraZeneca reported that its Phase 3 KESTREL trial of Imfinzi (durvalumab) failed to meet the primary endpoint of improving overall survival (OS) compared to the…
Galapagos and Gilead have halted the phase 3 ISABELA program, consisting of two studies evaluating ziritaxestat in patients with idiopathic pulmonary fibrosis (IPF). The decision…
The South African government, via South Africa Health Minister Dr. Zweli Mkhize, declared a temporary hold on the AstraZeneca (Oxford) vaccine studies in that nation…
Amgen released its financial results for the fourth quarter and full year 2020. Among the key results, Amgen disclosed that the development of five its…
Concert Pharmaceuticals reported that its Phase 2 trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did not meet the primary endpoint…
Biogen announced in its annual results and earnings presentation that its Phase II SPARK study of cinpanemab (BIIB054), under development for Parkinson’s disease, missed its primary and…
A Kuwait-based clinical trial sponsored by Indian generic drug producer Dr. Reddy’s Laboratory was recently terminated as the resulting data failed to evidence a statistically…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
